world-biomarkers-pharma-biotech-2017-posters

Volume10, Issue 12 (Suppl)

J Proteomics Bioinform, an open access journal

ISSN: 0974-276X

Page 103

conferenceseries

.com

World Biomarkers & Pharma Biotech 2017

December 07-09, 2017

December 07-09, 2017 | Madrid, Spain

International Conference on

PHARMACEUTICAL BIOTECHNOLOGY

WORLD BIOMARKERS CONGRESS

JOINT EVENT ON

J Proteomics Bioinform 2017, 10:12(Suppl)

DOI: 10.4172/0974-276X-C1-110

Silibinin downregulates E-cadherin expression in MKN-45 human gastric cancer cells

Ebrahim Faghihloo

Shahid Beheshti University of Medical Sciences, Iran

astric cancer is currently known as one of the most important causes of cancer-driven death, all over the world. In patients with

gastric cancer, a significant proportion of deaths occur due to metastasis. On the other hand, down modulated E-cadherin level

has been reported as an important contributor to tumor cell invasion and metastasis. In this regard, the present work was aimed

to evaluate the impact of silibinin, a flavonolignan with established anti-tumor efficacy, on cell viability and E-cadherin expression

in a gastric cancer cell line; MKN-45. To determine cell viability, MTT assay was performed 48 hours after silibinin treatment (at

concentrations of 100, 200 and 400 μM). In addition, quantitative real-time PCR was done following total RNA extraction and cDNA

synthesis, to assess E-cadherin level in cells treated with silibinin. The MTT results showed a silibinin concentration-dependent

reducing effect on the viability of MKN-45 cells. The findings of quantitative real-time PCR analysis demonstrated upregulated

E-cadherin expression in cells treated with silibinin (significantly at concentration of 200 μM) compared to control cells. The current

study suggests that silibinin may exert anti migratory/invasive effects on gastric cancer cells by enhancing E-cadherin expression,

which need to be further investigated.